financetom
Business
financetom
/
Business
/
BlackBerry Swings to Fiscal Q1 Non-GAAP Loss, Revenue Falls; Q2 Guidance Issued, Full-Year Outlook Reaffirmed -- Shares Rise After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BlackBerry Swings to Fiscal Q1 Non-GAAP Loss, Revenue Falls; Q2 Guidance Issued, Full-Year Outlook Reaffirmed -- Shares Rise After Hours
Jun 26, 2024 3:21 PM

05:52 PM EDT, 06/26/2024 (MT Newswires) -- BlackBerry (BB) reported fiscal Q1 non-GAAP loss late Wednesday of $0.03 per share, compared with earnings of $0.06 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.03.

Revenue for the quarter that ended May 31 was $144 million, down from $373 million a year earlier.

Analysts surveyed by Capital IQ expected $134.1 million.

For fiscal Q2, the company expects revenue ranging from $136 million to $144 million. Four analysts polled by Capital IQ expect $142.4 million.

For fiscal 2025, the company reaffirmed revenue guidance of $586 million to $616 million. Analysts are looking for $600.9 million.

Blackberry shares climbed more than 7% in recent after-hours activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gilead Sciences Receives FDA Approval for Updated Label of Biktarvy
Gilead Sciences Receives FDA Approval for Updated Label of Biktarvy
Apr 26, 2024
09:14 AM EDT, 04/26/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Friday that the US Food and Drug Administration has approved an updated label for its antiviral pill Biktarvy in virologically suppressed pregnant adults with human immunodeficiency virus 1, or HIV-1. The company said the label now includes additional data from a phase 1b study of Biktarvy which...
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy
Apr 26, 2024
09:15 AM EDT, 04/26/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Friday that a European regulator has recommended approval of Opdivo in combination with cisplatin and gemcitabine for the first-line treatment of adult patients having unresectable or metastatic urothelial carcinoma. The positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use is based on...
Saia CFO Douglas Col to Retire
Saia CFO Douglas Col to Retire
Apr 26, 2024
09:17 AM EDT, 04/26/2024 (MT Newswires) -- Saia ( SAIA ) said Friday that its chief financial officer, Douglas Col, will retire after 10 years with the transportation company. The company said Col will remain as CFO until a successor is named and will also serve as an advisor until the end of the year to ensure a smooth transition....
BRIEF-L Catterton Acquires Majority Stake In Kiko Milano From Percassi Family
BRIEF-L Catterton Acquires Majority Stake In Kiko Milano From Percassi Family
Apr 26, 2024
April 26 (Reuters) - L Catterton: * L CATTERTON ACQUIRES MAJORITY STAKE IN KIKO MILANO FROM PERCASSI FAMILY * L CATTERTON: TERMS OF TRANSACTION WERE NOT DISCLOSED Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved